SCHEMBL4865217

SCHEMBL4865217

O=C(O)c1ccc(Nc2cc(N3CCC3)ncn2)cc1

nearest known ligand 0.55

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.55
RAB9A P51151 3/20 0.53
ALDH1A1 P00352 2/20 0.53
MPL P40238 2/20 0.50
ABL1 P00519 1/20 0.47
BCR P11274 1/20 0.47
NPC1 O15118 2/20 0.47
ATM Q13315 1/20 0.47
CD274 Q9NZQ7 1/20 0.47
EGFR P00533 1/20 0.46
ERBB3 P21860 1/20 0.46
MAPK14 Q16539 1/20 0.44
AURKA O14965 3/20 0.44
LMNA P02545 1/20 0.43
MAPK10 P53779 1/20 0.43
SCN9A Q15858 1/20 0.43
AURKB Q96GD4 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4868204 0.86 SMN1; SMN2 (0.50) SMN1; SMN2RAB9AALDH1A1MPLABL1
SCHEMBL8798290 0.80 SMN1; SMN2 (0.59) SMN1; SMN2RAB9AALDH1A1ABL1BCR
SCHEMBL31660945 0.79 SMN1; SMN2 (0.61) SMN1; SMN2RAB9AALDH1A1ABL1BCR
SCHEMBL14421264 0.78 CD274 (0.55) SMN1; SMN2RAB9AALDH1A1ABL1BCR
SCHEMBL27741343 0.78 CD274 (0.55) SMN1; SMN2RAB9AALDH1A1ABL1BCR
SCHEMBL4724653 0.75 NPC1 (0.55) SMN1; SMN2RAB9ANPC1EGFRERBB3
SCHEMBL4872523 0.75 NPC1 (0.57) SMN1; SMN2RAB9ANPC1EGFRERBB3
SCHEMBL5244511 0.73 NPC1 (0.56) SMN1; SMN2RAB9ANPC1EGFRERBB3
SCHEMBL27401069 0.73 KMO (0.52) SMN1; SMN2RAB9AALDH1A1ABL1BCR
SCHEMBL31660951 0.72 CD274 (0.51) SMN1; SMN2RAB9AALDH1A1ABL1BCR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080076771-A1 Thrombopoietin Receptor Agonists REITER LAWRENCE A 2008-03-27 US disclosed
EP-1794156-A2 TROMBOPOIETIN RECEPTOR AGONISTS Pfizer Products Incorporated (US) 2007-06-13 EP disclosed
WO-2006033005-A2 THROMBOPOIETIN RECEPTOR AGONISTS PFIZER PRODUCTS INC. (US) 2006-03-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080076771-A1 Thrombopoietin Receptor Agonists MPL, THPO, TBXA2R SMN1; SMN2 3733/4885RAB9A 2219/4885ALDH1A1 2423/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.